CsA 2-h concentration correlates best with area under the concentration-time curve after allo-SCT compared with trough CsA

Bone Marrow Transplantation

Volumn 47, Issue 1, 2012, Pages 54-59

  Kong, D C M ^a   Shuttleworth, P ^b   Bailey, M ^a   Grigg, A ^b,c  

^a MONASH UNIVERSITY   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c AUSTIN HOSPITAL   (Australia)

Author keywords

CsA; monitoring; pharmacokinetics; SCT

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN A; FLUCONAZOLE; MULTIDRUG RESISTANCE PROTEIN 1; POSACONAZOLE;

ADOLESCENT; ADULT; AGE; ALLOGENEIC STEM CELL TRANSPLANTATION; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GRAFT VERSUS HOST REACTION; HUMAN; INFECTION; INFECTION PREVENTION; MALE; MAXIMUM PLASMA CONCENTRATION; MYELOABLATIVE CONDITIONING; NONMYELOABLATIVE CONDITIONING; PILOT STUDY; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AREA UNDER CURVE; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; P-GLYCOPROTEIN; POLYMORPHISM, GENETIC; STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84855749922     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2011.2     Document Type: Article

References (39)

1. Halloran PF, Helms LMH, Kung L, Noujaim J. The temporal profile of calcineurin inhibition by cyclosporine in vivo. Transplantation 1999; 68: 1356-1361.
2. Shultz KR, Nevill TJ, Balshaw RF, Toze CL, Corr T, Currie CJ et al. Effect of gastrointestinal inflammation and age on the pharmacokinetics of oral microemulsion cyclosporine A in the first month after bone marrow transplantation. Bone Marrow Transplant 2000; 26: 545-551.
3. Kahan BD, Welsh M, Schoenberg L, Rutzsky LP, Katz SM, Urbauer DL et al. Variable oral absorption of transplant recipients using cyclosporine. A biopharmaceutical risk factor for chronic renal allograft rejection. Transplantation 1996; 62: 599-606. (Pubitemid 26313901)
4. Warrens AN, Salama A, Waters JB, Lechler RI. Comparison of Neoral and Sandimmune preparation in renal transplant patients - Improved pharmacokinetics with Neoral. Transplant Proc 1996; 28: 2169-2170. (Pubitemid 26282411)
5. Duncan N, Craddock C. Optimizing the use of cyclosporine in allogeneic stem cell transplantation. Bone Marrow Transplant 2006; 38: 169-174. (Pubitemid 44102943)
6. Wingard JR, Nash RA, Przepiorka D, Klein JL, Weisdorf DJ, Fay JW et al. Relationship of tacrolimus (FK506) whole blood concentrations and efficacy and safety after HLA-identical sibling bone marrow transplantation. Bone Marrow Transplant 1998; 4: 157-163. (Pubitemid 128538807)
7. Kennedy MS, Yee GC, McGuire TR, Leonard TM, Crowley JJ, Deeg HJ. Correlation of serum cyclosporine concentration with renal dysfunction in marrow transplant recipients. Transplantation 1986; 40: 249-253.
8. Kahan BD, Grevel J. Optimization of cyclosporine therapy in renal transplantation by a pharmacokinetic strategy. Transplantation 1988; 46: 631-644. (Pubitemid 19017032)
9. Cantarovich M, Ross H, Arizón JM, Gómez MA, Straatman L, Orús J et al. Benefit of Neoral C2 monitoring in de novo cardiac transplant recipients receiving basiliximab induction. Transplantation 2008; 85: 992-999. (Pubitemid 351543163)
10. Caforio AL, Tona F, Piaserico S, Gambino A, Feltrin G, Fortina AB et al. C2 is superior to C0 as predictor of renal toxicity and rejection risk profile in stable heart transplant recipients. Transpl Int 2005; 18: 116-124. (Pubitemid 41742955)
11. Cantarovich M, Levy G, Burra P, Cavallari A, Duvoux C, Lake J et al. Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on 2-hr postdose levels (C2). Transplantation 2002; 73: 953-959. (Pubitemid 34252362)
12. Morris RG, Russ GR, Cervelli MJ, Juneja R, McDonald SP, Matthew TH. Comparison of trough, 2-h, and limited AUC blood sampling for monitoring cyclosporine (Neoral) at day 7 post-renal transplantation and incidence of rejection in the first month. Ther Drug Monit 2002; 24: 479-486. (Pubitemid 34857899)
13. Kim SJ, Prasad GVR, Huang M, Nash MM, Famure O, Park J et al. A comparison of the effects of C2-cyclosporine and C0-tacrolimus on renal function and cardiovascular risk factors in kidney transplant recipients. Transplantation 2006; 82: 924-930. (Pubitemid 44564039)
14. Kyllomen LE, Salmela KT. Early cyclosporine C0 and C2 monitoring in de novo kidney transplant patients: a prospective randomized single-centre pilot study. Transplantation 2006; 81: 1010-1015. (Pubitemid 43670434)
15. Hendriks MP, Blijlevens NMA, Schattenberg AVMB, Burger DM, Donnelly JP. Cyclosporin short infusion and C2 monitoring in haematopoietic stem cell transplant recipients. Bone Marrow Transplant 2006; 38: 521-525. (Pubitemid 44445358)
16. Barkholt L, Remberger M, Bodeard H, Ringdên O, Bottiger Y. Cyclosporin A (CsA) 2-h concentrations vary between patients without correlation to graft-versus-host disease after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant 2007; 40: 683-689. (Pubitemid 47456483)
17. Yee GC, Lennon TP, Gmur DG, Carlin J, Schaffer RL, Kennedy MS et al. Clinical pharmacology of cyclosporine in patients undergoing bone marrow transplantation. Transplant Proc 1986; 18: 153-159. (Pubitemid 17223791)
18. Bonhomme-Faivre L, Devocelle A, Saliba F, Chatled S, Maccario J, Farinotti R et al. MDR-1 C3435T polymorphism influences cyclosporine A dose requirements in liver transplant recipients. Transplantation 2004; 78: 21-25.
19. Lam S, Nilufar P, Ting LSL, Ensom MHH. Corticosteroid interactions with cyclosporine, tacrolimus, mycophenolate, and sirolumus: fact or fiction? Ann Pharmacother 2008; 42: 1037-1047.
20. Saad AH, DePeste DD, Carver PL. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy 2006; 26: 1730-1744. (Pubitemid 44885328)
21. Ruutu T, Volin L, Parkkali T, Jubonen E, Elonen E. Cyclosporine, methotrexate, and methylprednisolone compared with cyclosporine and methotrexate for the prevention of graft-versus-host disease in bone marrow transplantation from HLA-identical sibling donor: a prospective randomized study. Blood 2000; 96: 2391-2398.
22. Loor R, Pope L, Boyd R, Wood K, Bodepudi V. Monitoring cyclosporine of pre-dose and post-dose samples using nonextraction homogeneous immunoassay. Ther Drug Monit 2004; 26: 58-67. (Pubitemid 38140913)
23. Chapter 1. Review of mathematical fundamentals. In: Shargel L, Yu ABC (eds). Applied Biopharmaceutics and Pharmacokinetics, 3rd edn. Appleton & Lange: Stamford, CT, 1993, pp 6-9.
24. David OJ, Johnston A. Limited sampling strategies for estimating cyclosporine area under the concentration-time curve: review of current algorithms. Ther Drug Monit 2001; 23: 100-114. (Pubitemid 32240136)
25. International Neoral Renal Transplantation Study Group. Cyclosporin microemulsion (Neorals) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation. Am J Transplant 2002; 2: 148-156.
26. Lück R, Böger E, Kuse E, Klempnauer J, Nashan B. Achieving adequate cyclosporine exposure in liver transplant recipients: a novel strategy for monitoring and dosing using intravenous therapy. Liver Transpl 2004; 10: 686-691. (Pubitemid 38628231)
27. Knoop C, Vervier I, Thiry P, De Backer M, Kovarik JM, Rousseau A et al. Cyclosporine pharmacokinetics and dose monitoring after lung transplantation: comparison between cystic fibrosis and other conditions. Transplantation 2003; 76: 683-688. (Pubitemid 37072003)
28. Mahalati K, Belitsky P, Sketris I, West K, Panek R. Neoral monitoring by simplified sparse sampling area under the concentration-time curve. Transplantation 1999; 68: 55-62.
29. Jaksch P, Kocher A, Neuhauser P, Sarahrudi K, Seweryn J, Wisser W et al. Monitoring C2 level predicts exposure in maintenance lung transplant patients receiving the microemulsion formulation of cyclosporine (Neoral). J Heart Lung Transplant 2005; 24: 1076-1080. (Pubitemid 41127190)
30. Kovarik JM, Hoyer PF, Ettenger R, Punch J, Soergel M. Cyclosporine absorption profiles in pediatric kidney and liver transplant patients. Pediatr Nephrol 2003; 18: 1275-1279. (Pubitemid 37527104)
31. Cantarovich M, Barkun JS, Tchervenkov JI, Besner JG, Aspeslet L, Metrakos P. Comparison of Neoral dose monitoring with cyclosporine trough levels versus 2-hr postdose levels in stable liver transplantation. Transplantation 1998; 66: 1621-1627. (Pubitemid 29034981)
32. Levy G, Thervet E, Lake J, Uchida K. Patient management by Neoral C2 monitoring: an international consensus statement. Transplantation 2002; 73: S12-S18. (Pubitemid 34538824)
33. Vincenti F, Mendez R, Curtis J, Light J, Pearson T, Wu Y-M et al. A multicentre, prospective study of C2-monitored cyclosporine microemulsion in a US population of denovo renal transplant recipients. Transplantation 2005; 80: 910-916. (Pubitemid 41552886)
34. Nashan B, Bock A, Bosmans J-L, Budde K, de Fijter H, Jaques B et al. Use of Neoral C2 monitoring: a European consensus. Transpl Int 2005; 18: 768-778. (Pubitemid 41726805)
35. Morris RG, Ilett KF, Tett SE, Ray JE, Fullinfaw RO, Cooke R et al. Cyclosporin monitoring in Australasia: 2002 update of consensus guidelines. Ther Drug Monit 2002; 24: 677-688. (Pubitemid 35379519)
36. Genestier L, Fournel S, Flacher M, Assossou O, Revillard J-P, Bonnefoy-Berard N. Induction of Fas (Apo-1, CD95)-mediated apoptosis of activated lymphocytes by polyclonal antithymocyte globulin. Blood 1998; 91: 2360-2368. (Pubitemid 28155510)
37. Delaney MP, Smythe E, Higgins RM, Morris AG. Constitutive and acquired resistance to calcineurin inhibitors in renal transplantation: role of P-glycoprotein-170. Transpl Int 2000; 13: 276-284.
38. Sanquer S, Schwarzinger M, Maury S, Yakouben K, Rafi H, Pautas C et al. Calcineurin activity as a therapeutic index of immunosuppression: a functional, pharmacodynamic approach for GVHD. Transplantation 2004; 77: 854-858. (Pubitemid 38436823)
39. Sommerer C, Giese T, Schmidt J, Meuer S, Zeier M. Ciclosporin A tapering monitored by NFAT-regulated gene expression: a new concept of individual immunosuppression. Transplantation 2008; 85: 15-21.